A Phase I/IIa Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of an H5N1 Virus-Like Particle (VLP) Influenza Vaccine (Recombinant).

Trial Profile

A Phase I/IIa Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of an H5N1 Virus-Like Particle (VLP) Influenza Vaccine (Recombinant).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Jun 2013

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary)
  • Indications Influenza A virus H5N1 subtype; Influenza A virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 21 Mar 2012 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
    • 21 Mar 2012 Status changed from active, no longer recruiting to completedas reported by ClinicalTrials.gov.
    • 08 Sep 2011 Results published in the Journal of Virology, according to a Novavax media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top